COMPARATIVE EFFICACY OF FIRST-LINE DOCETAXEL plus CAPECITABINE (XT) VERSUS DOCETAXEL plus EPIRUBICIN (ET): POOLED ANALYSIS OF TWO RANDOMISED TRIALS

被引：0

作者：

Luporsi, E. ^{[1
]}

Bachelot, T. ^{[2
]}

Bajard, A. ^{[3
]}

Chinal, J. Provencal ^{[4
]}

Coeffic, D. ^{[5
]}

Platini, C. ^{[6
]}

Marcel, D. Dramais ^{[7
]}

Oprea, C. ^{[8
]}

Ferri-Dessems, R. ^{[9
]}

Perol, D. ^{[2
]}

机构：

[1] Ctr Alexis Vautrin, F-69373 Vandoeuvre Les Nancy, France

[2] Ctr Leon Berard, Lyon, France

[3] Hop Univ Strasbourg, Strasbourg, France

[4] CH Reg Annecy, Annecy, France

[5] Inst Privet Cancel, Grenoble, France

[6] Hop Bon Secours, Metz, France

[7] CH Valence, Valence, France

[8] Sanofi Aventis, Paris, France

[9] Gmo Oncohematol, Roche, Neuilly Seine, France

来源：

ANNALS OF ONCOLOGY | 2008年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：67 / 68

页数：2

共 50 条

[11] Docetaxel versus docetaxel plus bevacizumab in progressive castration-resistant prostate cancer following first-line docetaxel
Heidenreich, A.
Pfister, D. J.
Thueer, D.
Brehmer, B.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[12] Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2-negative breast cancer: a meta-analysis
Wu, Jie
Wang, Zhiqiang
Fu, Yi
BMC WOMENS HEALTH, 2025, 25 (01)
[13] A multicenter phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first line treatment in patients with locally advanced and metastatic breast cancer. Preliminary report
Mavroudis, D
Boukovinas, I
Ardavanis, A
Syrigos, K
Kouroussis, CH
Kakolyris, S
Malamos, N
Athanasiadis, A
Varthalitis, I
Potamianou, A
Georgoulias, V
BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S280 - S280
[14] Randomized, multicenter, phase III trial of docetaxel plus epirubicin (ET) with or without capecitabine (X) as first-line therapy for stage IV breast cancer (BC)
Mansutti, M.
Cavazzini, G.
Lorusso, V.
Boni, C.
Occelli, M.
Puglisi, F.
Del Mastro, L.
Venturini, M.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[15] Final Results of ERASME-4: A Randomized Trial of First-Line Docetaxel plus either Capecitabine or Epirubicin for Metastatic Breast Cancer
Bachelot, Thomas
Bajard, Agathe
Ray-Coquard, Isabelle
Provencal, Jocelyne
Coeffic, David
Agostini, Cecile
Boisseau, Martial
Kaphan, Regis
Dramais, Dominique
Oprea, Corina
Ferri-Dessens, Rose-Marie
Guastalla, Jean-Paul
Perol, David
ONCOLOGY, 2011, 80 (3-4) : 262 - 268
[16] Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma
Liu, Ying
Ye, Zhengbao
Xi, Wenqi
Ma, Tao
Shi, Min
Yang, Liu
Zhu, Zhenggang
Zhang, Jun
BIOMED RESEARCH INTERNATIONAL, 2013, 2013
[17] Trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: Phase II results
Gennatas, C. G.
Michalaki, V.
Gennatas, S.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[18] Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
Wardley, Andrew M.
Pivot, Xavier
Morales-Vasquez, Flavia
Zetina, Luis M.
Dias Gaui, Maria de Fatima
Reyes, Douglas Otero
Jassem, Jacek
Barton, Claire
Button, Peter
Hersberger, Veronica
Torres, Antonio Anton
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 976 - 983
[19] Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer
Li, Jinyu
You, Junhao
Si, Wen
Zhu, Yanyun
Chen, Yi
Yang, Bo
Han, Chun
Linghu, Ruixia
Zhang, Xingyang
Jiao, Shunchang
Yang, Junlan
MEDICINE, 2015, 94 (41)
[20] Safety and efficacy of the combination of trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: phase II results
Michalaki, V.
Gennatas, S.
Gennatas, C.
EJC SUPPLEMENTS, 2009, 7 (02): : 276 - 276

← 1 2 3 4 5 →